POSTN and neoplasm: We document pharmacological inhibition of pro-inflammatory cytokines POSTN and CCL2 in the TME following combinatorial treatment of erlotinib+MLN0128 and propose that the effectiveness of the dual therapy is a result of both direct anti-tumor activity and modulation of the TME [5,9,16,43].